BBIOHealthcareLarge-Cap
BridgeBio Pharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for BridgeBio Pharma, Inc. (BBIO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are BBIO insiders buying or selling?
BridgeBio Pharma, Inc. insiders reported 20 open-market buys ($210.2M) and 171 sells ($1.4B) across 191 Form 4 filings — a net selling position of $1.2B.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 13, 2026)
Total Form 4 filings
191
SEC EDGAR
Insider filers
23
Insider buys (20)
$210.2M
Insider sells (171)
$1.4B
Insider sentiment
Net sellingNet insider flow of $1.2B in net selling.
Recent BBIO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 13, 2026 | Andrea Ellis | Director | Sale | 17.2K | $84.00 | $1.4M |
| Jul 13, 2026 | Jennifer E. Cook | Director | Sale | 148.6K | $88.54 | $13.2M |
| Jun 24, 2026 | Jennifer E. Cook | Director | Sale | 39.4K | $69.92 | $2.8M |
| Jun 24, 2026 | Hannah Valantine | Director | Sale | 5.0K | $68.25 | $341.5K |
| Jun 17, 2026 | Jennifer E. Cook | Director | Sale | 90.2K | $66.62 | $6.0M |
| Jun 8, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $67.67 | $5.4M |
| May 26, 2026 | Neil Kumar | Chief Executive Officer | Sale | 26.1K | $69.44 | $1.8M |
| May 19, 2026 | Thomas Trimarchi | President and CFO | Sale | 13.7K | $65.08 | $888.4K |
| May 19, 2026 | Randal W. Scott | Director | Sale | 10.0K | $67.15 | $671.5K |
| May 11, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $67.40 | $5.4M |
| May 4, 2026 | Maricel Apuli | Chief Accounting Officer | Sale | 2.0K | $71.58 | $143.2K |
| Apr 13, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $74.61 | $6.0M |
| Mar 16, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $68.76 | $5.5M |
| Mar 12, 2026 | Hannah Valantine | Director | Sale | 8.7K | $72.00 | $624.3K |
| Mar 6, 2026 | Andrea Ellis | Director | Sale | 64.9K | $64.87 | $4.2M |
| Mar 3, 2026 | Hannah Valantine | Director | Sale | 25.5K | $67.41 | $1.7M |
| Feb 27, 2026 | Maricel Apuli | Chief Accounting Officer | Sale | 2.0K | $66.00 | $132.0K |
| Feb 23, 2026 | Neil Kumar | Chief Executive Officer | Sale | 28.1K | $71.39 | $2.0M |
| Feb 18, 2026 | Maricel Apuli | Chief Accounting Officer | Sale | 510 | $74.31 | $37.9K |
| Feb 18, 2026 | Thomas Trimarchi | President and CFO | Sale | 13.6K | $74.72 | $1.0M |
| Feb 18, 2026 | Randal W. Scott | Director | Sale | 10.0K | $75.46 | $754.6K |
| Feb 12, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $71.86 | $5.7M |
| Jan 13, 2026 | Neil Kumar | Chief Executive Officer | Sale | 80.0K | $75.54 | $6.0M |
| Dec 16, 2025 | Neil Kumar | Chief Executive Officer | Sale | 30.0K | $74.64 | $2.2M |
| Dec 10, 2025 | Maricel Apuli | Chief Accounting Officer | Sale | 2.0K | $74.26 | $148.5K |
Showing the 25 most recent of 191 Form 4 filings for BridgeBio Pharma, Inc..
Most active BBIO insiders
- Neil Kumar50 filings
- Brian C Stephenson28 filings
- Michael Thomas Henderson18 filings
- Hannah Valantine15 filings
- Cameron Turtle12 filings
Ask anything about BBIO insider activity
Use Trabud's AI agent to query BridgeBio Pharma, Inc.'s Form 4 history in plain English — "Show me BBIO CEO purchases this year" or compare it against any other ticker.
Open the AI agentBBIO insider trading FAQ
Are BridgeBio Pharma, Inc. insiders buying or selling?
Across 191 SEC Form 4 filings, BridgeBio Pharma, Inc. (BBIO) insiders reported 20 open-market purchases totaling $210.2M and 171 sales totaling $1.4B. That is a net selling position of $1.2B.
How many insiders trade BBIO stock?
23 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for BridgeBio Pharma, Inc.. The most recent filing was accepted on Jul 13, 2026.
Where does Trabud get BBIO insider trading data?
All BBIO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.